4-氨基嘧啶-5-羧酸 | 20737-41-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氨基嘧啶-5-羧酸
• 中文别名: 4-氨基嘧啶-5-甲酸
• 英文名称: 4-aminopyrimidine-5-carboxylic acid
• 英文别名: 4-Amino-pyrimidin-5-carbonsaeure；4-Amino-pyrimidin-carbonsaeure-(5)；4-amino-pyrimidin-5-carboxylic acid
• CAS: 20737-41-1
• 化学式: C₅H₅N₃O₂
• mdl: MFCD00047383
• 分子量: 139.114
• InChiKey: ZUBDZQFROMAIPT-UHFFFAOYSA-N

物化性质

• 熔点：
  278-281 °C(Solv: water (7732-18-5))
• 沸点：
  384.9±27.0 °C(Predicted)
• 密度：
  1.533±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89.1
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  室温和干燥环境中使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Aminopyrimidine-5-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Aminopyrimidine-5-carboxylic acid
CAS number: 20737-41-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H5N3O2
Molecular weight: 139.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用的4-氨基嘧啶-5-羧酸是一种医药中间体，据文献报道，它可用于制备杀菌药物4-氨基-5-嘧啶甲酰胺类化合物及抗肿瘤药物MNK抑制剂。

反应信息

• 作为反应物：
  描述：

  4-氨基嘧啶-5-羧酸 在 Crabtree's catalyst 、 铑 、 氘 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 4-Amino-2-deuteriopyrimidine-5-carboxylic acid
  参考文献：
  名称：

  10th international symposium on the synthesis and applications of isotopes and isotopically labelled compounds-synthesis of compounds labelled with long-lived isotopes Session 17, Thursday, June 18, 2009

  摘要：

  本篇是第一场会议的延续。文章详细介绍了一些制备氚标记化合物的方法，并讨论了在大于1居里的范围内处理氚的问题。此外，还详细描述了若干单个同位素标记化合物的制备方法。版权所有 © 2010 约翰威立父子有限公司。

  DOI：

  10.1002/jlcr.1773
• 作为产物：
  描述：

  4-氨基嘧啶-5-甲腈 在 sodium hydroxide 作用下， 生成 4-氨基嘧啶-5-羧酸
  参考文献：
  名称：

  65.简单的嘧啶。第一部分：光谱学研究

  摘要：

  DOI：

  10.1039/jr9530000331

文献信息

• SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Ajinomoto Co., Inc.

  公开号：US20160244451A1

  公开（公告）日：2016-08-25

  Provided is a sulfonamide derivative represented by the following general formula (1) and having an α4 integrin inhibitory effect with high selectivity with a low effect on α4β1 and a high effect on α4β7, or a pharmaceutically acceptable salt thereof (in the general formula (1), A, B, D, E, R 41 , and a to h are as described in the description).

  提供的是一种磺酰胺衍生物，其具有以下通式(1)表示，并具有对α4整合素抑制效果的高选择性，对α4β1影响小，对α4β7影响大，或其药用可接受盐（在通式(1)中，A、B、D、E、R 41 和a至h如描述中所述）。
• 作为MNK抑制剂的杂环化合物
  申请人：南京天印健华医药科技有限公司

  公开号：CN109020957B

  公开（公告）日：2023-01-13

  本发明涉及一类杂环化合物、含有其的药物组合物、以及它们的制备方法,和其作为丝裂原活化蛋白激酶相互作用激酶1和2‑MNK1/MNK2抑制剂的用途。该抑制剂为式(I)所示的杂环化合物，或其药学上可接受的盐、前药、溶剂化合物、多晶型体、异构体、稳定同位素衍生物或含有其的药物组合物。本发明涉及的化合物可用于治疗或预防由MNK介导的相关疾病，如癌症。
• Novel phenylalanine derivatives
  申请人：Sagi Kazuyuki

  公开号：US20050222141A1

  公开（公告）日：2005-10-06

  Specific phenylalanine derivatives and analogues thereof have an antagonistic activity to α4 integrin. They are used as therapeutic agents for various diseases concerning α4 integrin.

  特定的苯丙氨酸衍生物及其类似物具有对α4整合素的拮抗活性。它们被用作治疗涉及α4整合素的各种疾病的药物。
• The effect of adding Crabtree's catalyst to rhodium black in direct hydrogen isotope exchange reactions
  作者：Søren Christian Schou

  DOI：10.1002/jlcr.1612

  日期：2009.7

  A new catalytic system based on rhodium black using Crabtree's catalyst as an additive for direct hydrogen isotope exchange in aromatic compounds has been investigated. The level of deuterium incorporation can be improved from for example 16 to 93%. The new catalyst mixture tolerates a variety of solvents. Copyright © 2009 John Wiley & Sons, Ltd.

  一种基于黑铑的新催化系统已被研究，该系统使用克拉布特催化剂作为添加剂，用于芳香化合物的直接氢同位素交换。重氢掺入水平可以从例如16%提高到93%。这种新的催化剂混合物能够容忍多种溶剂。版权 © 2009 约翰·威利与 sons有限公司。
• Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity
  作者：Laurie B. Schenkel、Philip R. Olivieri、Alessandro A. Boezio、Holly L. Deak、Renee Emkey、Russell F. Graceffa、Hakan Gunaydin、Angel Guzman-Perez、Josie H. Lee、Yohannes Teffera、Weiya Wang、Beth D. Youngblood、Violeta L. Yu、Maosheng Zhang、Narender R. Gavva、Sonya G. Lehto、Stephanie Geuns-Meyer

  DOI：10.1021/acs.jmedchem.6b00039

  日期：2016.3.24

  developing a transient receptor potential A1 (TRPA1) antagonist for the treatment of pain due to a wealth of data implicating its role in pain pathways. Despite this, identification of a potent small molecule tool possessing pharmacokinetic properties allowing for robust in vivo target coverage has been challenging. Here we describe the optimization of a potent, selective series of quinazolinone-based

  由于大量数据暗示了其在疼痛途径中的作用，因此开发一种用于治疗疼痛的瞬时受体电位A1（TRPA1）拮抗剂引起了人们的极大兴趣。尽管如此，鉴定具有药代动力学特性以允许强大的体内靶标覆盖的有效小分子工具一直具有挑战性。在这里，我们描述了一种有效的，选择性的基于喹唑啉酮的TRPA1拮抗剂系列的优化。高通量筛选确定4，它们具有有希望的效价和选择性。一种策略旨在优化效能同时增加极性，以改善内在清除率，最终发现嘌呤酮27（AM-0902），这是一种有效的TRPA1选择性拮抗剂，具有药代动力学特性，可在体内对大鼠TRPA1 IC 50进行30倍以上的覆盖。化合物27在大鼠中表现出对AITC诱导的退缩的剂量依赖性抑制作用，从而证实了其作为研究TRPA1在体内疼痛模型中作用的工具的效用。